crouchingtigerhiddendragongreendestinysword| China's innovative pharmaceutical companies show their cancer treatment potential: ASCO clinical data is outstanding

News summary

CITIC Construction Investment Analysis, Chinese innovative pharmaceutical companies displayed at ASCO ConferencecrouchingtigerhiddendragongreendestinyswordWith BIC potentialcrouchingtigerhiddendragongreendestinyswordThe future clinical results have attracted much attention.

Newsletter text

Domestic pharmaceutical companies showcase new oncology drug research and development results at ASCO conference

At the high-profile ASCO conference, CITIC Construction Investment analysts revealed that China's innovative pharmaceutical companies have made significant progress in the field of cancer treatment. The research results show that the types of drugs developed by Chinese pharmaceutical companies include monoclonal antibodies, dual antibodies and ADCs, showing great potential in treating a variety of tumors. CITIC Construction Investment said that these innovative drugs have shown innovation in design, and clinical trial results have confirmed their excellent performance. Pharmaceutical companies 'products have shown strong clinical effects in treating a variety of tumors. Experts pointed out that China's innovative pharmaceutical companies continue to show growth momentum in the field of cancer treatment. A number of drugs have shown breakthrough potential in oncology indications and are expected to meet the BIC (Best-in-Class) standard. In the future, more clinical data on these drugs deserves close attention from investors.